Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
aTyr Pharma, Inc. (ATYR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: ATYR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -44.5% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 144.01M USD | Price to earnings Ratio - | 1Y Target Price 22 |
Price to earnings Ratio - | 1Y Target Price 22 | ||
Volume (30-day avg) 1826516 | Beta 1.21 | 52 Weeks Range 1.42 - 4.66 | Updated Date 03/29/2025 |
52 Weeks Range 1.42 - 4.66 | Updated Date 03/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.9 |
Earnings Date
Report Date 2025-03-12 | When Before Market | Estimate - | Actual -0.1809 |
Profitability
Profit Margin - | Operating Margin (TTM) -10633.5% |
Management Effectiveness
Return on Assets (TTM) -32.74% | Return on Equity (TTM) -61.76% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 79381776 | Price to Sales(TTM) 244.92 |
Enterprise Value 79381776 | Price to Sales(TTM) 244.92 | ||
Enterprise Value to Revenue 135 | Enterprise Value to EBITDA -0.81 | Shares Outstanding 75796200 | Shares Floating 73808822 |
Shares Outstanding 75796200 | Shares Floating 73808822 | ||
Percent Insiders 2.39 | Percent Institutions 64.48 |
Analyst Ratings
Rating 4.5 | Target Price 22 | Buy 4 | Strong Buy 4 |
Buy 4 | Strong Buy 4 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
aTyr Pharma, Inc.
Company Overview
History and Background
aTyr Pharma, Inc. was founded in 2003. The company is focused on developing therapeutics based on tRNA synthetase biology.
Core Business Areas
- Resolaris (withdrawn): Formerly a lead candidate for facioscapulohumeral muscular dystrophy (FSHD). Development was discontinued due to trial results.
- Efzofitimod: An investigational selective modulator of neuropilin-2 (NRP2) in clinical development for pulmonary sarcoidosis.
Leadership and Structure
John Mendlein is the Chairman. The leadership team includes various VPs and Directors overseeing clinical development, regulatory affairs, and other functions.
Top Products and Market Share
Key Offerings
- Efzofitimod: An investigational selective modulator of neuropilin-2 (NRP2) in clinical development for pulmonary sarcoidosis. There is no current market share data available as it is still in development. Competitors in the pulmonary sarcoidosis treatment space include corticosteroids, immunosuppressants, and potential emerging therapies from other pharmaceutical companies like Boehringer Ingelheim and Bristol Myers Squibb.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and constantly evolving. The development of novel therapeutics is driven by unmet medical needs and advances in scientific understanding.
Positioning
aTyr Pharma is positioned as a company focused on tRNA synthetase biology and developing therapies for severe diseases. Their competitive advantage, if successful, would be a novel mechanism of action addressing unmet needs.
Total Addressable Market (TAM)
The global pulmonary sarcoidosis market is estimated at $1.6 billion in 2023 and projected to reach $2.3 billion by 2033. aTyr's position depends on clinical trial success and market entry.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approach targeting tRNA synthetase biology
- Efzofitimod showing promise in early clinical trials
- Experienced management team
Weaknesses
- History of clinical trial failure (Resolaris)
- Limited financial resources
- Dependence on a single lead candidate (Efzofitimod)
- High risk of clinical trial failure inherent in drug development
Opportunities
- Positive clinical trial results for Efzofitimod
- Potential partnerships with larger pharmaceutical companies
- Expansion of pipeline to include additional tRNA synthetase targets
- Orphan drug designation benefits
Threats
- Clinical trial failure of Efzofitimod
- Competition from other companies developing therapies for pulmonary sarcoidosis
- Regulatory hurdles and delays
- Difficulty raising capital
Competitors and Market Share
Key Competitors
- GILD
- BMY
- JNJ
Competitive Landscape
aTyr Pharma faces significant competition from established pharmaceutical companies with greater resources and more advanced clinical programs. Its advantage lies in its unique tRNA synthetase biology approach, but it faces significant risks in clinical development and commercialization.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited due to the lack of commercial products.
Future Projections: Future growth depends on the successful development and commercialization of Efzofitimod and other pipeline candidates. Analyst estimates are highly speculative at this stage.
Recent Initiatives: Focusing on the clinical development of Efzofitimod for pulmonary sarcoidosis.
Summary
aTyr Pharma is a high-risk, high-reward company focused on developing novel therapeutics. Its future hinges on the success of Efzofitimod in clinical trials. The company's limited financial resources and history of clinical trial failures are significant challenges. However, positive clinical trial results and strategic partnerships could lead to significant growth.
Similar Companies
BMY
Bristol-Myers Squibb Company
BMY
Bristol-Myers Squibb Company
GILD
Gilead Sciences Inc
GILD
Gilead Sciences Inc
JNJ
Johnson & Johnson
JNJ
Johnson & Johnson
REGN
Regeneron Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Company Website
- Analyst Reports
- Industry News Sources
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on publicly available data and analyst estimates, which are subject to change. Investing in pharmaceutical companies is inherently risky, and investors should carefully consider their risk tolerance before investing.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About aTyr Pharma, Inc.
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2015-05-07 | President, CEO & Director Dr. Sanjay S. Shukla M.D., M.S. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 56 | Website https://www.atyrpharma.com |
Full time employees 56 | Website https://www.atyrpharma.com | ||
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.